Relmada Therapeutics, Inc. RLMD Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $26.88M-41.8% | $46.18M-15.7% | $54.81M-51.6% | $113.32M+25.1% | ||
| $32.22M-14.6% | $37.72M-22.9% | $48.89M+2.0% | $47.93M+36.6% | ||
| $59.1M-29.6% | $83.89M-19.1% | $103.7M-35.7% | $161.25M+28.3% | ||
| -$59.1M+29.6% | -$83.89M+19.1% | -$103.7M+35.7% | -$161.25M-28.3% | ||
| $1.72M-56.2% | $3.91M-20.3% | $4.91M+16.8% | $4.21M+8,803% | ||
| -$57.39M+28.3% | -$79.98M+19.0% | -$98.79M+37.1% | -$157.04M-24.9% | ||
| -$1.47+44.5% | -$2.65+19.0% | -$3.27+38.3% | -$5.30+25.8% | ||
| -$59.1M+29.6% | -$83.89M+19.1% | -$103.7M+35.7% | -$161.25M-28.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Relmada Therapeutics, Inc. profitable?
- Relmada Therapeutics, Inc. is not currently profitable: it reported a net loss of $58.9M over the trailing twelve months.
- What is Relmada Therapeutics, Inc.'s earnings per share?
- Relmada Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-1.11.
- Where does Relmada Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Relmada Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.